James R. Meyers

The year 2017 holds 24 of the 41 filings of James R. Meyers, published between February 21, 2017 and June 16, 2025. Thirty-three concern Gilead Sciences, Inc. (EVP Worldwide Commercial Ops) and 8 concern Sangamo Therapeutics, Inc, as Director.

The record contains 4 sales, all at Gilead, worth EUR 10.7 million in total with a median of EUR 2,328,906. Two of them carry the date January 16, 2018 (EUR 4,900,838 and EUR 1,640,009); the other is from August 31, 2017 (EUR 3,017,802). There is no purchase. The rest is 21 share grants, 4 option exercises and 12 filings of another kind.

After 2017 the pace drops: 9 filings in 2018, then 1 or 2 a year. No filing falls in the last twelve months. Publication follows the trade by a median of 4 days, across all 41 filings.

Trades by Meyers within 30 days of colleagues at Gilead Sciences, Inc. number 4, 4 and 2, every one in the same direction. Colleagues in order: Gregg H. Alton, John C. Martin and Gayle E. Wilson.